Evidence map›Paper›PMID 27057438›Full record

ArticleOncoimmunology2016

TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer.

Sylvian Bron, Luc Henry, Eveline Faes-Van't Hull, Riccardo Turrini, Dominique Vanhecke, Nicolas Guex, Assia Ifticene-Treboux, Emanuela Marina Iancu, Aikaterini Semilietof, Nathalie Rufer and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Macrophage Polarization States in the Tumor Microenvironment.International journal of molecular sciences · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Sylvian BronLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Luc HenryLudwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland; Institute of Chemical Sciences and Engineering (ISIC), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Eveline Faes-Van't HullLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Riccardo TurriniLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Dominique VanheckeLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Nicolas GuexVital-IT, Swiss Institute of Bioinformatics, University of Lausanne , Lausanne, Switzerland.
Assia Ifticene-TrebouxDepartment of Gynecology and Obstetrics, CHUV , Lausanne, Switzerland.
Emanuela Marina IancuLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Aikaterini SemilietofLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Nathalie RuferLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Hans-Anton LehrInstitute of Pathology, Johannes Gutenberg University , Mainz, Germany.
Ioannis XenariosVital-IT, Swiss Institute of Bioinformatics, University of Lausanne , Lausanne, Switzerland.
George CoukosLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
Jean-François DelaloyeDepartment of Gynecology and Obstetrics, CHUV , Lausanne, Switzerland.
Marie-Agnès DouceyLudwig Center for Cancer Research, University of Lausanne , Lausanne, Switzerland.
University of Lausanne · CHLudwig Cancer Research · CHHôpital Orthopédique de la Suisse Romande · CHJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In experimental mouse models of cancer, increasingly compelling evidence point toward a contribution of tumor associated macrophages (TAM) to tumor lymphangiogenesis. Corresponding experimental observations in human cancer remain scarce although lymphatic metastasis is widely recognized as a predominant route for tumor spread. We previously showed that, in malignant tumors of untreated breast cancer (BC) patients, TIE-2-expressing monocytes (TEM) are highly proangiogenic immunosuppressive cells and that TIE-2 and VEGFR signaling pathways drive TEM immunosuppressive function. We report here that, in human BC, TEM express the canonical lymphatic markers LYVE-1, Podoplanin, VEGFR-3 and PROX-1. Critically, both TEM acquisition of lymphatic markers and insertion into lymphatic vessels were observed in tumors but not in adjacent non-neoplastic tissues, suggesting that the tumor microenvironment shapes both TEM phenotype and spatial distribution. We assessed the lymphangiogenic activity of TEM isolated from dissociated primary breast tumors

Indexed as

Angiogenesisbreast cancerlymphaticsTIE-2-expressing monocytestumor microenvironment

Identifiers

PMID27057438
PMCPMC4801424
OpenAlexW2248198437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.